Ziv-aflibercept

Phase 2Protein / enzyme

Regeneron

Ziv-aflibercept is one of 549 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

548

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Pancreatic Neuroendocrine TumorActive, not recruiting

Malignant GliomaActive, not recruiting

Uveal MelanomaActive, not recruiting

Carcinoid TumorActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

MelanomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Pancreatic Neuroendocrine TumorPhase 2

Active, not recruiting

Malignant GliomaPhase 2

Active, not recruiting

Uveal MelanomaPhase 2

Active, not recruiting

Carcinoid TumorPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Fallopian Tube CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Ziv-aflibercept

Regeneron

Phase 2

1 2

Zolymbus

AbbVie

Preclinical

1 3

Chirocaine

PPurdue Pharma LP

Preclinical

1 4

Chantix

PPrism Pharmaceuticals

Preclinical

1 5

Vfend

PPrism Pharmaceuticals

Preclinical

—6

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 7

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 8

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 9

Bisphosphonate

Amgen

Preclinical

2 10

Recombinant Human Chorionic Gonadotropin

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Advanced Cancer

NCT02298959

Q4 2030

Phase 2Recruiting

Uveal Melanoma

NCT06121180

Clinical

Trials by Indication[1]

Lymphoma4 trials

VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Completed· Regeneron logo

Regeneron·Phase 1·NCT00036946

VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

Completed· Regeneron logo

Regeneron·Phase 1·NCT00045266

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Completed· Regeneron logo

Regeneron·Phase 1·NCT00083213·25 enrolled

Show 1 more trial

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Completed· Regeneron logo

Regeneron·Phase 1·NCT00082823·25 enrolled

Melanoma2 trials

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00450255·41 enrolled

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01258855·84 enrolled

Uveal Melanoma2 trials

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06121180·32 enrolled

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT03712904·3 enrolled

Metastatic Colorectal Cancer2 trials

Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy

Withdrawn·—·N/A·NCT01941173

Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer

Withdrawn·NNSABP Foundation Inc·Phase 2·NCT01889680

Carcinoid Tumor1 trial

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Completed·—·Phase 2·NCT01782443·19 enrolled

20 more indications

Soft Tissue Sarcoma1 trial

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00390234·63 enrolled

Malignant Glioma1 trial

VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00369590·58 enrolled

Non-Small Cell Lung Carcinoma1 trial

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT02192541·5 enrolled

Refractory Solid Tumors1 trial

Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00622414·27 enrolled

Glioblastoma Multiforme1 trial

Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00650923·61 enrolled

Metastatic Cancer1 trial

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00407485·22 enrolled

Breast Cancer1 trial

VEGF Trap in Treating Patients With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00369655·21 enrolled

Diabetic Macular Edema1 trial

The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 2/3·NCT02645734·133 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02101918·22 enrolled

Advanced Cancer1 trial

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02298959·59 enrolled

Fallopian Tube Cancer1 trial

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00436501·58 enrolled

Outcome1 trial

3 Month Outcome of Ziv-aflibercept for DME

Completed·MMarashi Eye Clinic·Phase 2/3·NCT02772497·10 enrolled

Myelodysplastic Syndromes1 trial

Aflibercept in Treating Patients With Myelodysplastic Syndromes

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00509249·18 enrolled

Small Cell Lung Cancer1 trial

S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00828139·189 enrolled

Endometrial Cancer1 trial

VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00462826·49 enrolled

Solid Tumors1 trial

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02159989·83 enrolled

Thyroid Cancer1 trial

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00729157·41 enrolled

Colorectal Cancer1 trial

Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer

Withdrawn·UUniversity of Southern California·Phase 2·NCT02235324

Gastric Cancer1 trial

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Completed·—·Phase 2·NCT01747551·64 enrolled

Unspecified1 trial

Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection

Unknown status·RRafic Hariri University Hospital·Phase 2·NCT02486484·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 31 trial records for Ziv-aflibercept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ziv-aflibercept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ziv-aflibercept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: Regeneron

Ziv-aflibercept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2030

Trials by Indication[1]

Lymphoma4 trials

Melanoma2 trials

Uveal Melanoma2 trials

Metastatic Colorectal Cancer2 trials

Carcinoid Tumor1 trial

Soft Tissue Sarcoma1 trial

Malignant Glioma1 trial

Non-Small Cell Lung Carcinoma1 trial

Refractory Solid Tumors1 trial

Glioblastoma Multiforme1 trial

Metastatic Cancer1 trial

Breast Cancer1 trial

Diabetic Macular Edema1 trial

Pancreatic Neuroendocrine Tumor1 trial

Advanced Cancer1 trial

Fallopian Tube Cancer1 trial

Outcome1 trial

Myelodysplastic Syndromes1 trial

Small Cell Lung Cancer1 trial

Endometrial Cancer1 trial

Solid Tumors1 trial

Thyroid Cancer1 trial

Colorectal Cancer1 trial

Gastric Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News